Urban and rural safety net health care system clinics: No disparity in HPV4 vaccine completion rates

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Sandri, Kelly Jo ^a   Verdenius, Inge ^b   Bartley, Mitchell J ^a   Else, Britney M ^a   Paynter, Christopher A ^a   Rosemergey, Beth E ^a   Harris, George D ^a   Malnar, Gerard J ^a   Harper, Sean M ^c   Griffith, R Stephen ^a   Bonham, Aaron J ^a   Harper, Diane M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c HAMPSHIRE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHILD; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; MEDICATION COMPLIANCE; NULLIGRAVIDA; NULLIPARA; PATIENT COMPLIANCE; RURAL POPULATION; SAFETY NET HOSPITAL; UNITED STATES; URBAN POPULATION; DOSE RESPONSE; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VACCINATION; VULNERABLE POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DELIVERY OF HEALTH CARE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MISSOURI; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RURAL POPULATION; URBAN POPULATION; VACCINATION; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84901217943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096277     Document Type: Article

References (40)

1. US Department of Health and Human Services (2011) 2010 National Healthcare Disparities Report. AHRQ Publication no. 11-0005. Available at www.ahrq.gov/qual/qrdr10.htm. Accessed on July 31, 2013.
2. Wu X, Watson M, Wilson R, Saraiya M, Cleveland JL, et al. (2012) Human Papillomavirus-Associated Cancers - United States, 2004-2008. MMWR 61: 258-261.
3. Spoont M, Greer N, Su J, Fitzgerald P, Rutks I, et al (2011) Rural vs. Urban Ambulatory Health Care: A Systematic Review. VA-ESP Project #09-009.
4. Krieger JL, Katz ML, Kam JA, Roberto A (2012) Appalachian and non-Appalachian pediatricians' encouragement of the human papillomavirus vaccine: implications for health disparities. Womens Health Issues. 22: e19-26.
5. Reiter PL, Katz ML, Paskett ED (2012) HPV vaccination among adolescent females from Appalachia: implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev. 21: 2220-30. doi:10.1158/1055-9965.
6. Mills LA, Head KJ, Vanderpool RC (2013) HPV vaccination among young adult women: a perspective from Appalachian Kentucky Prev Chronic Dis. 10: E17. doi:10.5888/pcd10.120183.
7. Moss JL, Gilkey MB, Reiter PL, Brewer NT (2012) Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008-2010. Cancer Epidemiol Biomarkers Prev 21: 1913-22.
8. Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, et al (2005) Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health. 21: 149-57. (Pubitemid 40463567)
9. Casey MM, Thiede Call K, Klingner JM (2001) Are rural residents less likely to obtain recommended preventive healthcare services? Am J Prev Med. 21: 182-8. (Pubitemid 32884255)
10. Regan J, Schempf AH, Yoon J, Politzer RM (2003) The role of federally funded health centers in serving the rural population. J Rural Health. 19: 115-24.
11. Frick KD, Regan J (2001) Whether and where community health center users obtain screening services. J Health Care Poor Underserved. 12: 429-45. (Pubitemid 33595187)
12. Adams SA, Bellinger JD, Gallagher A, Probst JC (2013) Report 1: Diffusion of Preventive Innovation: Racial and Rural Differences in Cervical Cancer Prevention and Control Practices. South Carolina Rural Health Research Center. Available at http://rhr.sph.sc.edu. Accessed 2013 July 31.
13. Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, et al (2013) Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE 8(8): e71295. doi:10.1371/journal.pone.0071295.
14. Markowitz LE, Dunne EF, Saraiya M, Lawson WH, Chesson H, et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-24.
15. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, et al (2013) Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial. JAMA. 309: 1793-1802. doi:10.1001/jama.2013.1625.
16. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, et al (2012) Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 30: 3572-9.
17. Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, et al (2011) Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 305: 1424-31.
18. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 103: 1444-51.
19. Harper DM, Vierthaler SL (2011) Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol. 2011: 457204.
20. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1): 100-10.
21. Szarewski AM, Skinner SR, Garland SM, Romanowski B, Schwarz TF, et al. (2013) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV Types (PATRICIA randomised trial): an unexpected observation. JID 208: 1391-6. doi:10.1093/infdis/jit360.
22. IBM Corp (2011) IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
23. IBM Corp (2012) Cochran-Armitage test for trend for 2xl tables. [updated Jan 4 2012] Available at: http://www-01.ibm.com/support/docview.wss?uid=swg214 80127. accessed 2013 July 31.
24. StatSoft, Inc (2010) STATISTICA (data analysis software system), version 9.1 Available from: www.statsoft.com. Accessed 2013 July 31.
25. Williams W, Lu PJ, Singleton JA, Bridges CB, Wortley PM, et al. (2012) Centers for Disease Control and Prevention. Adult Vaccination coverage - United States, 2010. MMWR 61: 66-72.
26. Dorell C, Stokely S, Yankey D, Jeyarajah J, MacNeil J, et al (2011) Centers for Disease Control and Prevention. National and State Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2011. MMWR 60: 671-677.
27. Tiro JA, Pruitt SL, Bruce CM, Persaud D, Lau M, et al (2012) Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 30: 2368-75.
28. Perkins RB, Brogly SB, Adams WG, Freund KM (2012) Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health (Larchmt). 21(8): 813-20.
29. Cook RL, Zhang J, Mullins J, Kauf T, Brumback B, et al. (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 47(6): 596-9.
30. Grant D, Hurley J, Williams H, McLaulin S, Rollins L, et al (2012) Department of Health and Human Services. Office of Inspector General. Vaccines for Children Program: Vulnerabilities in vaccine management. OEI-04-10-00430 June 2012. https://oig.hhs.gov/oei/reports/oei-04-10-00430.asp. Accessed 2013 August 1.
31. Setia S, Mainzer H, Washington ML, Coil G, Snyder R, et al (2002) Frequency and causes of vaccine wastage. Vaccine. 20: 1148-56. (Pubitemid 34135951)
32. Raymond P (2011) Rhode Island Department of Health. HPV4 Immunization Program Update. November 30, 2011 Available at http://www.health.ri.gov/ publications/policies/HPVVaccinePolicyUpdate.pdf. Accessed 2013 August 1.
33. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, et al (2010) Cervical cancer prevention: new tools and old barriers. Cancer. 116: 2531-42.
34. Schootman M, Fuortes LJ (1999) Breast and cervical carcinoma: the correlation of activity limitations and rurality with screening, disease incidence, and mortality. Cancer. 86: 1087-94. (Pubitemid 29439866)
35. Hopenhayn C, King JB, Christian A, Huang B, Christian WJ (2008) Variability of cervical cancer rates across 5 Appalachian states, 1998-2003. Cancer. 113: 2974-80.
36. Battaglia TA, Santana MC, Bak S, Gokhale M, Lash TL, et al (2010) Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer. 116: 913-21. doi:10.1002/cncr.24851.
37. Probst JC, Moore CG, Baxley EG (2005) Update: health insurance and utilization of care among rural adolescents. J Rural Health. 21: 279-87. (Pubitemid 41346041)
38. Martin A, Probst JC, Moore CG, Patterson D, Elder K (2005) Report 17: Trends in Uninsurance among Rural minority children. South Carolina Rural Health Research Center. Available at http://rhr.sph.sc.edu. Accessed 2013 July 31.
39. Heitmann ER, Harper DM (2012) Prophylactic HPV vaccines and prevention of cervical intraepithelial neoplasia. urrent Obstetrics and Gynecology Reports. 1, 95-105.
40. Demarteau N, Breuer T, Standaert B (2012) Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 30: 337-53.